AIM: The multi-tyrosine kinase inhibitor pazopanib prolongs progression-free survival (PFS) versus placebo in treatment-naive and cytokine-refractory metastatic clear-cell renal cell carcinoma (ccRCC). Outcomes and safety data with pazopanib after targeted therapy (TT) are limited. METHODS: We retrospectively evaluated records of consecutive patients with metastatic ccRCC who had progressive disease (PD) after TT and received pazopanib from November 2009 through November 2011. Tumour response was assessed by a blinded radiologist using Response Evaluation Criteria In Solid Tumours (RECIST). PFS and overall survival (OS) were estimated by Kaplan-Meier methods. RESULTS: Ninety-three patients were identified. Median number of prior TTs was 2 (range, 1-5). There were 68 events (PD or death). Among 85 evaluable patients, 13 (15%) had a partial response. Median PFS was 6.5 months (95% CI: 4.5-9.7); median OS was 18.1 months (95% CI: 10.26-NA). Common adverse events (AEs) included fatigue (44%), elevated transaminases (35%), diarrhoea (30%), hypothyroidism (18%), nausea/vomiting (17%), anorexia (14%) and hypertension exacerbation (14%); 91% of AEs were grade 1/2. Eleven patients (12%) discontinued therapy due to AEs. There were no treatment-related deaths. CONCLUDING STATEMENT: Pazopanib demonstrated efficacy in patients with metastatic ccRCC after PD with other TTs. Toxicity overall was mild/moderate and manageable.
AIM: The multi-tyrosine kinase inhibitor pazopanib prolongs progression-free survival (PFS) versus placebo in treatment-naive and cytokine-refractory metastatic clear-cell renal cell carcinoma (ccRCC). Outcomes and safety data with pazopanib after targeted therapy (TT) are limited. METHODS: We retrospectively evaluated records of consecutive patients with metastatic ccRCC who had progressive disease (PD) after TT and received pazopanib from November 2009 through November 2011. Tumour response was assessed by a blinded radiologist using Response Evaluation Criteria In Solid Tumours (RECIST). PFS and overall survival (OS) were estimated by Kaplan-Meier methods. RESULTS: Ninety-three patients were identified. Median number of prior TTs was 2 (range, 1-5). There were 68 events (PD or death). Among 85 evaluable patients, 13 (15%) had a partial response. Median PFS was 6.5 months (95% CI: 4.5-9.7); median OS was 18.1 months (95% CI: 10.26-NA). Common adverse events (AEs) included fatigue (44%), elevated transaminases (35%), diarrhoea (30%), hypothyroidism (18%), nausea/vomiting (17%), anorexia (14%) and hypertension exacerbation (14%); 91% of AEs were grade 1/2. Eleven patients (12%) discontinued therapy due to AEs. There were no treatment-related deaths. CONCLUDING STATEMENT: Pazopanib demonstrated efficacy in patients with metastatic ccRCC after PD with other TTs. Toxicity overall was mild/moderate and manageable.
Authors: Robert J Motzer; Dmitry Nosov; Timothy Eisen; Igor Bondarenko; Vladimir Lesovoy; Oleg Lipatov; Piotr Tomczak; Oleksiy Lyulko; Anna Alyasova; Mihai Harza; Mikhail Kogan; Boris Y Alekseev; Cora N Sternberg; Cezary Szczylik; David Cella; Cristina Ivanescu; Andrew Krivoshik; Andrew Strahs; Brooke Esteves; Anna Berkenblit; Thomas E Hutson Journal: J Clin Oncol Date: 2013-09-09 Impact factor: 44.544
Authors: Tarek M Mekhail; Rony M Abou-Jawde; Gabriel Boumerhi; Sareena Malhi; Laura Wood; Paul Elson; Ronald Bukowski Journal: J Clin Oncol Date: 2005-02-01 Impact factor: 44.544
Authors: M P Sablin; S Negrier; A Ravaud; S Oudard; C Balleyguier; J Gautier; C Celier; J Medioni; B Escudier Journal: J Urol Date: 2009-05-17 Impact factor: 7.450
Authors: Christian Eichelberg; Roman Heuer; Felix K Chun; Kristin Hinrichs; Mario Zacharias; Hartwig Huland; Hans Heinzer Journal: Eur Urol Date: 2008-08-08 Impact factor: 20.096
Authors: Robert J Motzer; Bernard Escudier; Stéphane Oudard; Thomas E Hutson; Camillo Porta; Sergio Bracarda; Viktor Grünwald; John A Thompson; Robert A Figlin; Norbert Hollaender; Gladys Urbanowitz; William J Berg; Andrea Kay; David Lebwohl; Alain Ravaud Journal: Lancet Date: 2008-07-22 Impact factor: 79.321
Authors: Cora N Sternberg; Ian D Davis; Jozef Mardiak; Cezary Szczylik; Eunsik Lee; John Wagstaff; Carlos H Barrios; Pamela Salman; Oleg A Gladkov; Alexander Kavina; Juan J Zarbá; Mei Chen; Lauren McCann; Lini Pandite; Debasish F Roychowdhury; Robert E Hawkins Journal: J Clin Oncol Date: 2010-01-25 Impact factor: 44.544
Authors: Sarathi Kalra; Bradley J Atkinson; Marc Ryan Matrana; Surena F Matin; Christopher G Wood; Jose A Karam; Pheroze Tamboli; Kanishka Sircar; Priya Rao; Paul G Corn; Nizar M Tannir; Eric Jonasch Journal: BJU Int Date: 2015-07-06 Impact factor: 5.588
Authors: Marc R Matrana; Tharakeswara Bathala; Matthew T Campbell; Cihan Duran; Aditya Shetty; Purnima Teegavarapu; Sarathi Kalra; Lianchun Xiao; Bradley Atkinson; Paul Corn; Eric Jonasch; Nizar M Tannir Journal: BJU Int Date: 2015-12-13 Impact factor: 5.588
Authors: S Nazha; S Tanguay; A Kapoor; M Jewett; C Kollmannsberger; L Wood; G Bjarnason; D Heng; D Soulières; N Reaume; N Basappa; E Lévesque; A Dragomir Journal: Curr Oncol Date: 2018-12-01 Impact factor: 3.677
Authors: B Milojkovic Kerklaan; M P J Lolkema; L A Devriese; E E Voest; A Nol-Boekel; M Mergui-Roelvink; M Langenberg; K Mykulowycz; J Stoebenau; S Lane; P Legenne; P Wissel; D A Smith; B J Giantonio; J H M Schellens; P O Witteveen Journal: Br J Cancer Date: 2015-08-20 Impact factor: 7.640
Authors: Michela Roberto; Maria Bassanelli; Elsa Iannicelli; Silvana Giacinti; Chiara D'Antonio; Anna Maria Aschelter; Paolo Marchetti Journal: Case Rep Oncol Med Date: 2015-12-20